Refractory Multiple Myeloma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 46 expanded access programs, clinical trials, and compassionate use pathways listed for Refractory Multiple Myeloma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with refractory multiple myeloma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 35 programs are currently active or recruiting, with the remaining 11 in other lifecycle stages. Sponsors actively running programs in this area include National Cancer Institute (NCI), Mayo Clinic, Massachusetts General Hospital, Alliance for Clinical Trials in Oncology, Andrew Yee, MD, and others.
By recruiting status
Snapshot of where every Refractory Multiple Myeloma program currently sits in its lifecycle.
- Active / Recruiting35
- Inactive11
Top sponsors
Organisations running the most Refractory Multiple Myeloma programs in the directory.
- National Cancer Institute (NCI)28 programs
- Mayo Clinic3 programs
- Massachusetts General Hospital2 programs
- Alliance for Clinical Trials in Oncology1 program
- Andrew Yee, MD1 program
- Carl Ola Landgren, MD, PhD1 program
- Fred Hutchinson Cancer Center1 program
- Indapta Therapeutics, INC.1 program
- Janssen Research & Development, LLC1 program
- Multiple Myeloma Research Consortium1 program
Refractory Multiple Myeloma programs (46)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Dasatinib and Quercetin with CAR-T Therapy for Treating Relapsed or Hard-to-Treat Multiple Myeloma — Mayo Clinic
- Study on Elotuzumab, Iberdomide, and Dexamethasone After Ide-Cel for Relapsed and Refractory Multiple Myeloma — Omar Nadeem, MD
- Study on Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — Carl Ola Landgren, MD, PhD
- Study on Using Infliximab to Prevent Cytokine Release Syndrome During Teclistamab or Talquetamab Treatment in Patients with Relapsed or Resistant Myeloma — Naresh Bumma
- Study on Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma — Massachusetts General Hospital
- Study on Lenalidomide for Treating Multiple Myeloma in Patients Undergoing Stem Cell Transplant — National Cancer Institute (NCI)
- MMRC Horizon One Adaptive Platform Trial for Evaluating Treatments in Relapsed or Refractory Multiple Myeloma — Multiple Myeloma Research Consortium
- Study of Selinexor with Carfilzomib, Isatuximab, and Dexamethasone for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — Natalie Callander
- Study on Genetic Testing-Directed Targeted Therapy for Advanced Solid Tumors, Lymphomas, or Multiple Myeloma — National Cancer Institute (NCI)
- Study on Ado-Trastuzumab Emtansine for Cancers with HER2 Genetic Changes — National Cancer Institute (NCI)
- Study on Afatinib for Cancers with HER2 Genetic Changes (MATCH-Subprotocol B) — National Cancer Institute (NCI)
- Testing Afatinib for Treating Cancers with EGFR Genetic Changes — National Cancer Institute (NCI)
- Study on AZD1775 for Treating Cancers with BRCA Genetic Changes — National Cancer Institute (NCI)
- Study on AZD9291 for Treating Cancers with EGFR Genetic Changes — National Cancer Institute (NCI)
- Study on BVD-523FB (Ulixertinib) for Cancers with Specific Genetic Changes — National Cancer Institute (NCI)
- Study on Copanlisib for Treating Cancers with PIK3CA Mutations — National Cancer Institute (NCI)
- Study on Copanlisib for Treating Cancers with PTEN Gene Changes — National Cancer Institute (NCI)
- Study on Crizotinib for Cancers with ROS1 Genetic Changes (MATCH-Subprotocol G) — National Cancer Institute (NCI)
- Study on Crizotinib for Treating Cancers with MET Exon 14 Deletion Genetic Changes — National Cancer Institute (NCI)
- Study on GDC-0032 (Taselisib) for Treating Cancers with PIK3CA Genetic Changes — National Cancer Institute (NCI)
- Study on Vismodegib for Treating Cancers with Specific Genetic Mutations — National Cancer Institute (NCI)
- Study on GSK2636771 for Treating Cancers with PTEN Genetic Changes — National Cancer Institute (NCI)
- Testing GSK2636771 for Cancers with PTEN Loss of Expression — National Cancer Institute (NCI)
- Study on Ipatasertib for Treating Cancers with AKT Genetic Changes — National Cancer Institute (NCI)
- Study on Erdafitinib for Treating Cancers with FGFR Gene Amplifications — National Cancer Institute (NCI)
- Study on LOXO-101 for Treating Cancers with NTRK Genetic Changes — National Cancer Institute (NCI)
- Study on MLN0128 (TAK-228) for Cancers with mTOR Genetic Changes — National Cancer Institute (NCI)
- Study on MLN0128 (TAK-228) for Cancers with TSC1 or TSC2 Genetic Changes — National Cancer Institute (NCI)
- Study on Sunitinib for Treating Cancers with cKIT Genetic Changes — National Cancer Institute (NCI)
- Study on New Medication Combination for Treating Relapsed Multiple Myeloma — National Cancer Institute (NCI)
- Testing Trametinib and Dabrafenib for Cancers with BRAF Genetic Changes — National Cancer Institute (NCI)
- Study on Trametinib for Treating Cancers with BRAF Genetic Changes — National Cancer Institute (NCI)
- Study on Trametinib for Cancers with GNAQ or GNA11 Genetic Changes — National Cancer Institute (NCI)
- Testing Trametinib for Cancers with NF1 Genetic Changes (MATCH-Subprotocol S1) — National Cancer Institute (NCI)
- Study on VS-6063 (Defactinib) for Cancers with NF2 Genetic Changes — National Cancer Institute (NCI)
- Phase II Study of Daratumumab, Clarithromycin, Pomalidomide, and Dexamethasone for Multiple Myeloma Patients Previously Treated with Daratumumab — Weill Medical College of Cornell University
- Study on Preventive Treatments for Taste Changes Caused by Talquetamab — Janssen Research & Development, LLC
- Study on Different Doses and Schedules of Belantamab Mafodotin for Treating Resistant Multiple Myeloma — Mayo Clinic
- Study on Daratumumab, Carfilzomib, Pomalidomide, and Dexamethasone for Treating Relapsed and Resistant Multiple Myeloma — Andrew Yee, MD
- Study on Elranatamab for Relapsed/Refractory Multiple Myeloma — Massachusetts General Hospital
- Study on IDP-023 Alone and with Antibody Therapies for Advanced Blood Cancers — Indapta Therapeutics, INC.
- Study on Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for Treating Relapsed or Resistant Multiple Myeloma — University of Washington
- Study on Mezigdomide, Carfilzomib, and Dexamethasone for Treating Relapsed or Resistant Multiple Myeloma with Tumors Outside the Bone Marrow — Roswell Park Cancer Institute
- Study on Adjusting Linvoseltamab Dosage for Treating Relapsed or Resistant Multiple Myeloma — Fred Hutchinson Cancer Center
- Study on Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for Treating Relapsed Refractory Multiple Myeloma (SCOPE Trial) — Mayo Clinic
- Study on Combining Two Approved Drugs and One Experimental Drug for Patients with Relapsed or Hard-to-Treat Multiple Myeloma — Alliance for Clinical Trials in Oncology
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Refractory Multiple Myeloma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.